Cytarabine -daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine and Daunorubicin at a fixed synergistic molar ratio of 5:1. Cytarabine -daunorubicin improves secondary acute myeloid leukemia. Cytarabine -daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia [1] [2].
In Vitro, Cytarabine-daunorubicin is 5 times more potent against FLT3-ITD leukemic blasts than against wild-type leukemic blasts[1].
References:
[1]. Lancet JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36(26):2684-2692.
[2]. Peterlin P, et al. CPX 351 as first line treatment in higher risk MDS. A phase II trial by the GFM[J]. Blood, 2021, 138: 243.
In Vitro, Cytarabine-daunorubicin is 5 times more potent against FLT3-ITD leukemic blasts than against wild-type leukemic blasts[1].
References:
[1]. Lancet JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36(26):2684-2692.
[2]. Peterlin P, et al. CPX 351 as first line treatment in higher risk MDS. A phase II trial by the GFM[J]. Blood, 2021, 138: 243.